About STINGINN, LLC
STINGINN, LLC focuses on harnessing the innate immune system to combat infectious disease, inflammation, and cancer through STING signaling pathway research. The company has received FDA approval for Phase I clinical trials and has secured multiple STTR grants for various therapeutic developments.
Development of STING activators for anti-tumor and anti-viral therapiesCreation of STAV technology to stimulate immune response against cancerDesign of oncolytic viruses that reconstitute STING signaling in tumor cellsDevelopment of STING inhibitors for the treatment of inflammatory disordersCreation of a recombinant VSV-HTLV-1 vaccine for HTLV-1-associated diseases
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to STINGINN, LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.